- Home
- CLDX
as 07-26-2024 4:00pm EST
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HAMPTON |
| Market Cap: | 2.4B | IPO Year: | 2008 |
| Target Price: | $66.00 | AVG Volume (30 days): | 679.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.11 - $53.18 | Next Earning Date: | 08-06-2024 |
| Revenue: | $6,072,000 | Revenue Growth: | 92.76% |
| Revenue Growth (this year): | -59.7% | Revenue Growth (next year): | 2.05% |
Stock Insider Trading Activity of Celldex Therapeutics Inc. (CLDX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Martin Samuel Bates | CLDX | SVP AND CFO | Jun 14 '24 | Sell | $35.42 | 17,172 | $608,314.67 | 28,125 | SEC Form 4 |
| Crowley Elizabeth | CLDX | SR. VP & CPDO | Jun 14 '24 | Sell | $34.87 | 30,000 | $1,045,962.00 | 9,074 | SEC Form 4 |
| Crowley Elizabeth | CLDX | SR. VP & CPDO | Jun 7 '24 | Sell | $35.06 | 15,000 | $525,873.00 | 9,074 | SEC Form 4 |
| Young Diane C. | CLDX | SVP, CHIEF MEDICAL OFFICER | Jun 7 '24 | Sell | $35.26 | 45,000 | $1,586,844.00 | 2,115 | SEC Form 4 |
| Wright Richard M. | CLDX | SR. VP & CCO | Jun 3 '24 | Sell | $33.99 | 19,264 | $654,694.75 | 20,833 | SEC Form 4 |
| Wright Richard M. | CLDX | SR. VP & CCO | Jun 3 '24 | Sell | $33.53 | 27,580 | $924,658.11 | 40,097 | SEC Form 4 |
| Heath-Chiozzi Margo | CLDX | SVP OF REGULATORY AFFAIRS | Jun 3 '24 | Sell | $33.65 | 58,369 | $1,964,087.67 | 13,383 | SEC Form 4 |
| Jimenez Freddy A. | CLDX | SVP & GENERAL COUNSEL | Jun 3 '24 | Sell | $33.60 | 8,006 | $269,002.40 | 25,924 | SEC Form 4 |
| Martin Samuel Bates | CLDX | SVP AND CFO | May 30 '24 | Sell | $34.05 | 35,000 | $1,191,774.50 | 25,128 | SEC Form 4 |
| Crowley Elizabeth | CLDX | SR. VP & CPDO | May 30 '24 | Sell | $33.64 | 38,597 | $1,298,383.78 | 9,074 | SEC Form 4 |
| Cavanaugh Sarah | CLDX | SVP OF CORP AFFAIRS & ADMIN. | May 30 '24 | Sell | $33.73 | 20,853 | $703,334.15 | 1,860 | SEC Form 4 |
Latest Celldex Therapeutics Inc. News
CLDX Breaking Stock News: Dive into CLDX Ticker-Specific Updates for Smart Investing
BioPharma Dive
10 days ago
Caribou lays off staff; Roche walks away from Relay
MT Newswires
10 days ago
Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation
GlobeNewswire
11 days ago
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 06/12/2024
GuruFocus.com
a month ago
Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...
MT Newswires
a month ago
Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing
MT Newswires
2 months ago
Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target
GuruFocus.com
2 months ago
Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
Compare CLDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLDX Celldex Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.